​Ovarian

• (101-21) A Phase 1 Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients with Advanced Solid Tumors
• (114-19) A Phase 1, open label, first-in-human study of TR1801-ADC, an antibody drug conjugate (ADC), in patients with select solid tumors expressing c-Met
• (137-19) Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas

• (152-17) Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

• (155-17) 0C 17-1: Phase 1 Multi-center Study of the Safety Pharmacokinetics and Preliminary Efficacy of CBT-101 in Subjects with Advanced Solid Tumors and C-Met Dysregulation

• (167-18) A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
• (178-18) A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
• (187-17) Trial of ZW25 in Patients With Advanced HER2-expressing Cancers

• (187-19) A Phase 1/2 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer

• (188-18) A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors

• (205-19) Study to Assess AFM24 in Advanced Solid Cancers

• (221-19) Study of GNX102 in Patients With Advanced Solid Tumors

Certain clinical trials may not be listed on ClinicalTrials.gov. To learn more about these or other clinical trials, please call 949-764-5543 or contact us online.